HIGH

Philips Azurion Systems Recalled Due to Software Issues

Philips recalled 990 Azurion Systems on December 8, 2025, after nine software issues were identified. The defects may cause loss of X-ray functionality, system restarts, and other operational failures. Healthcare providers must stop using the devices immediately.

Quick Facts at a Glance

Recall Date
December 8, 2025
Hazard Level
HIGH
Brand
PHILIPS MEDICAL SYSTEMS NEDERLAND B.V.
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL

Hazard Information

Nine (9) identified software issues which may result in the following: loss of X-ray after Pedal Tap, loss of X-ray after Phase Fault, missing live X-ray on the FlexVision monitor, system continues to restart, AMD triple drive, C-Partition of Suite PC running out of free space, system remains in continuous restart mode after start-up, misalignment of Marker Tool Overlay, longitudinal position error.

What You Should Do

Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact PHILIPS MEDICAL SYSTEMS NEDERLAND B.V. or your healthcare provider for instructions. Notification method: E-Mail

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Product Details

The recall involves Philips Azurion Systems R3.0, including models 722229, 722230, 722231, 722232, 722235, 722236, 722233, and 722234. The systems were distributed worldwide, including the US and various countries. These models were sold globally.

The Hazard

Nine software issues may cause loss of X-ray after pedal tap, missing live X-ray on the FlexVision monitor, and continuous system restarts. These malfunctions could compromise patient safety and diagnostic capabilities.

Reported Incidents

There have been no reported injuries or deaths related to the software malfunctions as of the recall date. The potential for harm remains high due to the critical nature of medical imaging.

What to Do

Stop using the affected devices immediately. Contact Philips Medical Systems Nederland B.V. or your healthcare provider for further instructions. Follow the recall instructions provided by the manufacturer.

Contact Information

For more information, email Philips Medical Systems Nederland B.V. at the contact address provided in the recall notice.

Key Facts

  • Recalled models include Azurion 3 M12, M15, Azurion 5 M12, M20, and Azurion 7 models
  • Nine software issues identified
  • Stop using devices immediately
  • Contact Philips for instructions

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERAL
Injury Types
OTHER

Product Classification

Product Details

Model Numbers
Software Version: R3.0. 1. Model Number: 722229. UDI Numbers: (01)00884838116726(21)22
(01)00884838116726(21)15
(01)00884838116726(21)16
(01)00884838116726(21)6
(01)00884838116726(21)8
+15 more
Affected States
ALL
Report Date
January 21, 2026
Recall Status
ACTIVE

Related Recalls

HIGH

Fresenius Kabi Vancomycin Injection Recalled Over Sterility Concerns

Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.

Fresenius Kabi Compounding
Lack of
Read more
HIGH

Fresenius Kabi Compounding Issues Recall of Vancomycin Injection

Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.

Fresenius Kabi Compounding
Lack of
Read more
HIGH

Pro Numb Tattoo Numbing Spray Recalled Due to cGMP Violations

Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.

PRO NUMB SENSITIVE SKIN
cGMP deviations
Read more